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Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors of the gastrointestinal tract that are believed
to originate from a neoplastic transformation of the intestinal pacemaker cells (interstitial cells of Cajal) normally
found in the bowel wall or their precursors. Although the microscopic features have been known for a long
time, the defining characteristic of GIST is the presence of the cell-surface antigen CD117 (KIT), which is
demonstrated by immunohistochemistry. KIT, which is a growth factor transmembrane receptor, is the
product of the proto-oncogene c-kit (chromosome 4). Surgical removal remains the only curative treatment for
patients with GISTs. Tumor size, mitotic index, anatomic location, tumor rupture and disease-free interval
are the classic characteristics used to predict the clinical course of patients who undergo complete gross
resection.
Most GISTs express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor
receptor alpha (PDGFRA) that are potential therapeutic targets for imatinib mesylate. Imatinib mesylate is
a rationally designed, molecularly specific oral anticancer agent that selectively inhibits several protein
tyrosine kinases central to the pathogenesis of human cancer and which has demonstrated remarkable
clinical efficacy in patients with chronic myeloid leukemia and malignant GISTs. More recently Sunitinib,
a new KIT/PDGFRA kinase inhibitor, has been tested in patients with GIST resistant to imatinib, with promising
results.
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introduction
Gastrointestinal stromal tumors (GISTs) are specific
mesenchymal tumors that may develop not only throughout
the whole gastrointestinal (GI) tract but also in the omentum
and mesentery. They range from small, benign, incidentally
detected nodules to large malignant tumors. It has been
suggested that GISTs originate from the interstitial cells of
Cajal, which are intestinal pacemakers [1]. They derive from
the myeloid stem cells, are positive for the CD34 antigen in
52%–72% of cases [2] and are frequently marked by the
presence of the c-kit proto-oncogene (85%–94%). Cajal cells
present both smooth muscle and neural cells, and neoplastic
Cajal cells might preferentially express one, both or neither of
these features, thus explaining the variant forms of GISTs.
Although relatively rare, GISTs make up the largest subset of
mesenchymal tumors of the GI tract and are reported to
comprise 5% of all sarcomas [3–5]. The estimated annual
incidence is 10–20 cases per million, of which 20%–30% are
malignant, although, following the recent clearer definition of
the diagnostic criteria for GISTs, it may be necessary to
revise these estimates [3].
GISTs occur in both sexes with similar frequency, but
several reported data have shown a preponderance in males,
generally after the fourth decade, with most studies finding
a mean age at diagnosis of 60 years. They are occasionally
found in young adults, although extremely rare in children [4].
Such tumors may occur anywhere in the GI tract but are
most commonly found in the stomach (4%–70%) and small
intestine (20%–40%). Only 5%–15% are found in the colon
and rectum, 5% in the esophagus and in the omentum and
rarely in the mesentery or retroperitoneum [5].
Surgical removal remains the only curative treatment for
patients with GISTs. Tumor size, mitotic index, anatomic
location, tumor rupture and disease-free interval are the
classic features used to predict the clinical course of patients
who undergo complete gross resection. Imatinib mesylate is
a rationally designed, molecularly specific oral anticancer
agent that selectively inhibits several protein tyrosine kinases
central to the pathogenesis of human cancer which has
demonstrated remarkable clinical efficacy in patients with
chronic myeloid leukemia and malignant GISTs. More
recently Sunitinib, a new KIT/PDGFRA kinase inhibitor, has
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promising results. The aim of this review is to clarify some
aspect of histopathological diagnosis of GISTs and to review
the most recent update in the medical management of
GISTs [6, 7].
historical overview
Until 20 years ago, most mesenchymal tumors of the digestive
tract were considered to be of smooth muscle or perineural
origin. In 1983, Mazur and Clark [8] reported that many
supposed smooth muscle tumors lacked immunohistochemical
or electron microscopic evidence of smooth muscle or neural
immunoreactivity, and they suggested that the neutral term
gastric stromal tumor would be more appropriate. Kindblom
et al. [9] proposed that such tumors might originate from the
interstitial cell of Cajal, an intestinal pacemaker cell, and
suggested the name GI pacemaker cell tumor.
The term GIST was gradually adopted for a specific category
of benign and malignant mesenchymal neoplasms of the GI
tract with a minimal or incomplete myogenic or neural
phenotype (uncommitted phenotype) as defined by
immunohistochemistry or electron microscopy. Tumors
exhibiting true smooth muscle or Schwann cell (neural)
differentiation are excluded. Although rare, GISTs are the
most common mesenchymal tumors of the GI tract.
It has become clear that the tumor cells comprising GIST are
closely related to the interstitial cells of Cajal [10, 11]. These
cells constitute a complex cellular network, the likely functions
of which are GI tract pacemaking and the regulation of
intestinal motility. The immunohistochemistry of the
interstitial cells of Cajal is similar to that of GIST cells, being
positive for KIT [9, 12]. However, some GISTs arise from the
mesentery or omentum, which lacks interstitial cells of Cajal,
suggesting an origin in multipotential mesenchymal stem cells
of Cajal cell lineage [13, 14].
pathology of GIST
Grossly, GISTs vary greatly in size, ranging from 1–2 cm
to >20 cm in diameter. Upon gross examination, an untreated
GIST is in most cases a friable mass that appears to arise in
the muscle rather than in the epithelium of the GI tract; the
tumors are often well circumscribed and unencapsulated,
although a pseudocapsule may occasionally be seen. Large
tumors may show cystic degeneration, necrosis and focal
hemorrhage and may rupture at the time of surgical resection.
Although extraluminal in origin, GISTs may ulcerate through
the overlying mucosa [15].
Microscopically, 70% of GISTs appear as spindle cell tumors,
20% are epithelioid in appearance with the remainder having
either a mixed spindle/epithelioid cell appearance or
occasionally a carcinoid-like/paragangioma-like appearance
[1]. The prognostic relevance of cell type seems limited,
although in the past it was often suggested that the mitotic
threshold for malignancy was lower in epithelioid tumors than
in spindle cell tumors. GISTs of spindle cell type are composed
typically of relatively uniform eosinophilic cells arranged in
short fascicles or whorls. The tumor cells have paler
eosinophilic cytoplasm than smooth muscle neoplasms, with
syncytial appearance; nuclei tend to be uniform in appearance
and more ovoid or shorter than those of a smooth muscle
cytoplasm, often with vesicular chromatin. GISTs of
epithelioid type are composed of rounded cells with variably
eosinophilic or clear cytoplasm.
Epithelioid lesions, similar to spindle cell lesions, tend to
have uniform round-to-ovoid nuclei with vesicular chromatin,
and this subset of tumors shows a nested architecture more
often than spindle cell cases, enhancing the risk of confusion
with an epithelial or melanocytic neoplasm. Lesions of mixed
cell type may exhibit an abrupt transition between spindle
cell and epithelioid areas (necessitating careful sampling if
both patterns are to be recognized) or may have a complex
comingling of these cell types throughout, leading to an
intermediate ovoid cytologic appearance.
immunophenotype
Although the microscopic features have been known for
a long time, the defining characteristic of GIST is the
presence of the cell-surface antigen CD117 (KIT), which is
demonstrated by immunohistochemistry [16]. KIT, which is
a growth factor transmembrane receptor, is the product of
the proto-oncogene c-kit (chromosome 4). As a member of
the tyrosine kinase receptor, KIT is closely related to the
receptors for platelet-derived growth factor and other
receptors of this family. KIT is expressed by hematopoietic
progenitor cells, mast cells, germ cells and interstitial cells of
Cajal. Activation of the KIT receptor by its ligand, known as
stem-cell factor (SCF), leads to cascades involved in
oncogenesis, including proliferation, adhesion, apoptosis and
differentiation [16].
KIT positivity in GISTs is typically strong and global.
Membrane staining is often present, and this pattern is more
readily observed in epithelioid GISTs. Many GISTs also have
paranuclear KIT-positive dots (Golgi-zone pattern), and
spindle cell tumors usually have a pan-cytoplasmic appearing
staining pattern, probably because membrane staining in these
cells is difficult to observe due to the narrow cross-dimension
of the spindle cells. Some epithelioid GISTs of the stomach
are less uniformly positive (and sometimes only weakly
positive) for KIT; the molecular correlation of this finding is
under investigation.
The term GIST should apply only to neoplasms
displaying KIT immunopositivity with very rare exceptions.
Such exceptions might include lesions with typical
cytoarchitectural features of GIST but which appear to be
immunohistochemically inert (e.g., due to some type of
fixation artefact, excessive heat during section drying or very
prolonged storage of unstained slides), are KIT negative due
to sampling error (e.g., very small needle biopsies showing
normal internal control staining for other antigens from
tumors in which KIT staining is focal in distribution), have
(in rare cases) ceased to express KIT due to some form of
clonal evolution, perhaps following STI-571 therapy, or in
the very small percentage (<2%) of otherwise typical tumors
that lack either KIT mutations and/or KIT overexpression.
Tumors in these exceptional categories should be labeled
spindle cell (or epithelioid) stromal neoplasm most
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consistent with GIST [5] and should be considered for
molecular analysis for KIT or PDGFRA mutations.
Immunohistochemistry should be performed without antigen
retrieval since this may yield false-positive CD117 staining;
similarly, Bouin fixation should be avoided since it may impair
the feasibility of molecular analysis on fixed samples.
Approximately 70%–80% of GISTs are also positive for
CD34, a hematopoietic progenitor cell antigen also present in
endothelial cells and subsets of fibroblasts and many neoplasms
related to these cell types. GISTs of the esophagus and
rectum are more consistently CD34 positive than are the
gastric and small intestinal GISTs. Approximately 30% of
GISTs, especially gastric and small intestinal tumors, are
positive for smooth muscle actin (SMA), whose expression
tends to be reciprocal with that of CD34; sometimes this is seen
in one tumor where CD34-positive and actin-negative areas
and CD34-negative and actin-positive areas are present. S100
protein expression is relatively rare in GISTs and occurs most
commonly in the small intestine (10%). The positivity is
usually focal, but is present in both cytoplasm and nuclei,
and most likely represents true expression of this antigen.
Positivity for desmin, the muscle-type intermediate filament
protein, is rare in GISTs at all sites but has been observed
relatively more often among esophageal GISTs [17]. Like
most mesenchymal tumors, especially those that are malignant,
GISTs are positive for vimentin. Keratin positivity is rare
(approximately 10% of cases) and can be seen with
antibodies reacting to keratin 18 and, to a lesser degree, to
keratin 8 [18].
Attempts to correlate cellular morphology with
immunophenotype have not been successful. Two-thirds of
spindle cell tumors express desmin and muscle actin but
usually in <10% of the tumor cells. Only 20% express
desmin and 40% express SMA in a diffuse manner. Of the
round cell tumors, <10% express desmin and SMA. Myxoid
tumors, with demonstrated smooth muscle differentiation,
can be confused with mucin-producing adenocarcinoma or
neoplasms with clear cell or signet-ring cell features.
Furthermore, cellular morphology can be misleading, since
tumors undistinguishable from schwannoma have revealed
strong desmin expression. However, schwannomas are
negative for CD117 and CD34 and positive for S-100 [19].
molecular analysis of GISTs
Most GISTs express constitutively activated mutant isoforms
of KIT or kinase PDGFRA.
KIT is an oncogenic receptor tyrosine kinase (RTK)
activated by binding with its ligand SCF. The KIT activation
results in phosphorylation of various substrates that mediate
intracellular signal transduction. KIT receptor is composed
by an extracellular region of five immunoglobulin-like loops,
followed by a transmembrane domain, an intracellular domain
which contains a negative regulatory juxtamembrane domain
and a tyrosine kinase which presents regions: the ATP-binding
pocket and the phosphotransferase catalytic site. Similar to
KIT, PDGFRA is also a RTK with similar structure, and in
GIST, the KIT or PDGFRA mutations cause phosphorylation,
constitutive activation of these kinase receptors and its
downstream signal. These receptors are potential therapeutic
targets for imatinib mesylate [20], which is a c-kit/PDGFR
tyrosine kinase inhibitor, acting on c-kit and PDGFR activity
by binding to the ATP site and preventing the activation of
PI-3K.
More than 90% of GIST present KIT mutations occurring
mainly in exon 11 (50%–77%), exon 9 (10%–18%), exon 13
(1%–4%) and exon 17 (1%–4%).
The exon 11 mutation frequency among low-risk patients
was of 87%, while exon 9 mutations were more frequent in
frankly malignant GIST (17%) than low- or high-risk tumors
(3% each).
On the other hand, patients whose tumors contained exon 11
KIT mutations had a longer event-free and overall survival
than those whose tumors expressed either exon 9 KIT
mutations or had no detectable kinase mutation. Exon 11
mutations had a higher response to imatinib and longer time
to progression than those with exon 9 mutations. Regarding
PDGFRA mutations, these occur mainly in exon 18 (4%–7%),
exon 12 (2%–6%) and exon 14 (<1%) [21].
In conclusion, mutations of KIT or PDGFRA are found in
the vast majority of GISTs, and the mutational status of these
oncoproteins is predictive of clinical response to imatinib.
PDGFRA mutations may explain response and sensitivity to
imatinib in some GISTs-lacking KIT mutations.
prognosis
GISTs are generally thought to be malignant, but they have
different degrees of aggressiveness, which result in different
times for the development of metastases. Predicting the
potential biological behavior of these tumors remains
difficult and an analysis of the literature to resolve this issue
provides many conflicting reports. Tumor size, mitotic
activity, tumor necrosis, histological type and pattern,
immunohistochemical profile, staining for proliferating
antigens and ploidy status, among others, have all been
evaluated extensively in this context without any consensus
being established.
The most important and easily applicable morphologic
criteria for prediction of tumor behavior are tumor size
(maximum diameter in centimeters) and mitotic rate. These
criteria should be applied together, and they form the current
basis of prognostic evaluation by pathologists. However, the
significance of size is site dependent; specifically, gastric tumors
tend to be less aggressive than intestinal tumors, even
those >5 cm in size, provided that their mitotic activity is
low, no more than five of 50 high-power fields (HPFs). Most
GISTs of <2 cm have negligible mitotic activity (usually less
than five of 50 HPFs). Such tumors are largely benign in all
sites when completely removed.
A consensus statement [6] has suggested that patients with
GISTs may be categorized into very low, low, intermediate
and high-risk tumors on the basis of an estimation of their
potential for recurrence and metastasis. Very low-risk tumors
are defined as tumors of <2 cm with fewer than five mitoses
per 50 HPFs. Low-risk tumors are defined as tumors
of between 2 and 5 cm with fewer than five mitoses per
50 HPF. Intermediate risk tumors are defined as tumors
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of <5 cm with six to 10 mitoses per 50 HPF or tumors of
between 5 and 10 cm with fewer than five mitoses per 50 HPF.
High-risk tumors are defined as tumors >5 cm with more
than five mitoses per 50 HPF, tumors >10 cm with any mitotic
rate or any size tumors with >10 mitoses per 50 HPF [2, 6].
Nevertheless, the subjectiveness and lack of concordance
between observers during mitotic counting are important
limitations to this method; factors such as size and number
of fields examined, tissue section thickness, variation in tumor
cellularity and in tumor cell size, morphological criteria for
the identification of mitotic figures and fastidiousness of the
observer, bias the results and reduce the reproducibility of
this criterion [2, 6].
molecular pattern of resistance to
imatinib
The KIT or PDGFRA RTKs are constitutively activated by
gain-of-function mutations in most GISTs, and these
mutations are early events in GIST oncogenesis.
Clinical responses to imatinib depend on the exonic location
of KIT mutations in GIST, and 10%–20% of GIST patients
exhibit primary resistance to imatinib.
Primary resistance is generally defined as progression
within the first 6 months of imatinib treatment. This
progression is generally multifocal and this subgroup of
GISTs usually expresses wild-type KIT or mutations in
exon 9 of KIT or mutated PDGFRA with a D842V mutation.
Secondary resistance is therefore defined as resistance
occurring beyond this 6-month period and is the result of
selection for additional point mutation in the KIT kinase
domains. On the other hand, there are also nonidentified
mutations in the nonresistant GIST.
Two mechanisms explain how those secondary mutations
can induce resistance to imatinib: first, the mutation can
stabilize the active conformation of the KIT kinase preventing
the imatinib binding, and second, the mutation may interfere
with imatinib binding without affecting kinase conformation.
Usually, most resistant tumors with a secondary mutation
had primary mutations in exon 11. The second site mutations
are mainly substitutions involving exon 13, 14 and 17 KIT
corresponding to the kinase domain [22–24]. Recent study
suggests that primary kit mutations in exon 13 K642E [5]
and in exon 14 T670I were associated with acquired
resistance [25].
All these mutations alter the secondary structure of the
kinase domain with the resulting alteration of the interaction
between imatinib and the receptor.
A frequent secondary mutation involves the exon 13 codon
654 (V654A) which decreases the binding affinity between
imatinib and the receptor and increases the sensitivity to low
concentrations of SCF [26].
A second mutation that may confer imatinib resistance is
located in exon 11 cod816 (D816V), since this activates
the kinase domain conformation, and the receptor is unable
to bind the imatinib [26]. Cells with these mutations showed
more sensitivity to nilotinib, a phenylaminopyrimidine related
to imatinib but in any case was insufficient as an adequate
treatment choice.
A third mutation involved in KIT secondary mutation is in
exon 17; these are essentially substitutions involving N822K,
D820Y and Y823D [24–27]. In untreated GIST, the incidence
if exon 13, 14 and 17 mutations is 1%.
Moreover, secondary resistance occurs according to two
different patterns of partial and multifocal resistance. In the
first subgroup, in which one or a limited number of
metastases show an enlargement but the other sites remain
controlled by imatinib, a multidisciplinary approach is
considered, and possible strategies include the combination
of locoregional approaches and either an increased dosage of
imatinib or an alternative experimental targeted therapy. On
the other hand, in the second subgroup, increasing the dose
of imatinib or an alternative targeted therapy are both
potentially suitable strategies, while surgery or radiofrequency
ablation are less useful.
The multitargeted KIT inhibitor sunitinib has proven
effective in some patients with imatinib-resistant GIST and
has achieved regulatory approval for this clinical indication,
whereas other novel inhibitors of KIT, such as PKC412, show
promising preclinical activity against certain imatinib-resistant
mutations in GISTs.
sunitinib
Sunitinib is an orally administered small molecule that
inhibits multiple RTKs. Sutent (Pfizer, Inc., New York, NY)
is the malate salt of sunitinib. Targets of sunitinib include
vascular endothelial growth factor receptors (VEGFR1,
VEGFR2 and VEGFR3), platelet-derived growth factor
receptors (PDGFRA and PDGFR beta), SCF receptor (KIT),
Fms-like tyrosine kinase-3 (FLT3), colony-stimulating factor
receptor type 1 (CSF-1R) and the glial cell line-derived
neurotrophic factor receptor (RET). The ability of sunitib to
target multiple tyrosine kinases in addition to kit has
suggested that it might be active in imatinib-resistant
tumors [28].
The study [29] supporting the approval of sunitinib for
second-line treatment of GIST is a randomized, double-blind
clinical trial performed in 56 centers in Asia, Europe and
North America, including 22 centers in the United States.
Eligible patients were adults with radiographically measurable
GISTs following either documented progression on or
intolerance to imatinib. Treatment was administered in
repeated 6-week cycles. Patients received either oral sunitinib
malate (50 mg) or placebo daily for 4 weeks followed by
2 weeks of rest (schedule 4/2). Following Response Evaluation
Criteria in Solid Tumors-defined disease progression, patients
on the placebo arm who met crossover eligibility criteria
were offered the opportunity to receive open-label sunitinib.
The primary end point was time-to-tumor progression
(TTP). Secondary end points included overall survival,
progression-free survival (PFS) and confirmed objective
response rate.
Three hundred and twelve patients randomly assigned 2:1
to sunitinib versus placebo comprised the intention-to-treat
population. After 149 progression events had occurred, the first
interim analysis for efficacy revealed that patients receiving
sunitinib experienced a more than four-fold increase in
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median TTP from 6.4 to 27.3 weeks (hazard ratio, 0.33;
95% confidence interval, 0.23, 0.47; log-rank P < 0.0001).
Further data are warranted to confirm this preliminary
observations.
conclusion
GISTs are relatively rare neoplasms of the GI tract that may
have a potentially lethal clinical outcome. Classification of
GISTs by pathologist has been controversial because the
histologic appearance of GIST is often consistent with other
tumors such as leiomyomas and leiomyosarcomas.
Molecular-targeted therapy can be effective in the
advanced disease setting, resulting in major tumor responses.
Antitumor activity may be highly predictable by assessing
tumor molecular biology.
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